Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Your guide to ASX market sectors
Opinions
Worried about a stock market crash? I'd buy these 5 rock-solid ASX shares to ride it out
Growth Shares
Experts name 3 of the best ASX growth shares to buy in November
Share Market News
3 ASX 200 directors buying up their company shares this week
Share Market News
5 things to watch on the ASX 200 on Tuesday
Growth Shares
Experts say these are the ASX 200 shares to buy next week
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
3 ASX 200 companies that could benefit from a falling Aussie dollar
Healthcare Shares
Move over gold: Could ASX 200 healthcare shares be the new 'safe-haven' investments?
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Not all ASX 200 shares are getting hammered today. Here are some winners
Growth Shares
Here are 3 top ASX growth shares that analysts rate as buys
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
